Abstract Objectives: We sought to evaluate whether clinical, lesion-related and procedural factors may predict in-stent restenosis (ISR) after intracranial stenting. Methods: Sixty-one Chinese patients with 65 lesions treated with single bare metal balloonmounted stent for symptomatic intracranial arterial stenosis underwent conventional angiographic follow-up after procedures between March 2004 and July 2009. Clinical, lesion-related and procedural factors were analysed for any predictive power for the ISR using univariate and multivariate analysis. ISR was defined as >50% stenosis within or at the edge of the stent or absolute luminal loss >20%. Results: ISR was found in 18 patients (18/61, 29.5%) with 20 lesions (20/65, 30.8%) at a median follow-up of 7 months (range, 5e30 months). Univariate analysis revealed that diabetes, Mori classification, lesion length and stent diameter were associated with ISR. In addition, diabetes (hazard ratio (HR), 2.661; 95% confidence interval (CI), 1.044e6.787; P Z 0.040) and lesion length (HR, 1.206; 95% CI, 1.023e1.421; P Z 0.026) were detected as two independent predictors for ISR by stepwise multivariate Cox regression analysis. Conclusions: ISR after intracranial stenting with bare metal balloon-mounted stents in our series seems to be more frequent than those reported by the majority of the published case series. Diabetes and lesion length are associated with increased risk of ISR. ª
Atherosclerotic stenosis of the major intracranial arteries is a high-risk cause of ischaemic stroke, which accounts for 30e50% of strokes in Asia 1 and 8e10% in North America 2 each year. The WarfarineAspirin for Symptomatic Intracranial Disease study (WASID) revealed that despite best anti-thrombotic therapy, the rate of ischaemic stroke ipsilateral to the intracranial high-grade (50e99%) stenotic artery was nearly 12% at 1 year 3 and the risk for a subsequent stroke was highest in the subgroup of patients with a stenosis >70%. 4 For these reasons, patients with symptomatic high-grade stenoses intractable to medical therapy might benefit from an interventional therapy.
A major concern for using bare metal stents for symptomatic intracranial stenosis has been the rate of in-stent restenosis (ISR), reported to be as high as 32%. 5 The pathogenesis of ISR remains poorly understood and identifying the predictors for ISR may allow some insights into the underlying ISR mechanisms. Furthermore, because ISR is associated with a high rate of recurrent neurologic events (transient ischaemic attack (TIA) stroke or death), 5, 6 the identification of risk factors can help to predict ISR after stent placement. A few clinical and anatomic characteristics correlating with ISR after intracranial stent placement have been reported previously. 5,7e9 However, there are no data on lesion characteristics as a predictor of ISR. In the present study, we analysed the value of different dependent variables in predicting ISR including clinical and procedural variables, and lesion-related characteristics, including the Mori classification. 10, 11 Patients and Methods
Study patients
This retrospective analysis and the protocol of this study received the approval of our institutional review board. Written informed consent was obtained from each patient prior to the initial procedure and follow-up angiography.
Nanjing Stroke Registry Program (NSRP) with a standardised protocol 12 included and identified a total of 84 patients who failed optimal medical therapy of symptomatic intracranial atherosclerotic stenosis (!50%) and then underwent attempted treatment with a single bare metal balloon-mounted stent at Jinling Hospital between March 2004 and July 2009. Failure of optimal medical therapy was defined as recurrent stroke or TIA despite treatment with anti-platelet therapy (aspirin, clopidogrel or a combination thereof) and a cholesterol-lowering agent (statin). Patients beyond at least 7 days of an ischaemic stroke were advised to receive stenting if necessary in our centre. Among the 84 patients who had 90 intracranial atherosclerotic lesions treated with single bare metal balloon-mounted stent, 61 patients with 65 lesions had angiographic follow-up at a median of 7 months (range, 5e30 months) after the procedure and are the focus of this study.
Definition
Using the WASID technique, 3 ISR was defined as a lesion demonstrating >50% stenosis with or at the edge of the stent; or absolute luminal loss >20% at angiographic followup when some lesions were left with residual stenosis measuring between 30% and 50% after the initial treatment. 13 In the Mori classification system, atherosclerotic lesions are classified into three groups by length and geometry. 10, 11 Mori A lesions were short (<5 mm in length), concentric or moderately eccentric, less than totally occlusive. Mori B lesions were tubular (5e10 mm in length), extremely eccentric or total occlusive, and less than 3 months old, and Mori C lesions were diffuse (>10 mm in length), extremely angulated (>90 ) or total occluded and 3 months old or older. The morphologic characteristics of lesions identified by angiography were defined in accordance with the American Heart Association/American College of Cardiology classification as modified by Ellis et. al.
14 Lesion length was measured as the distance between proximal and distal shoulders of the original lesion (before the procedure). Lesion ulceration was considered present if luminal contour were markedly irregular with overhanging margins or a small crater. A lesion was considered as eccentric if its lumen was in the outer one-quarter diameter of the apparent normal lumen. A lesion was classified as having an irregular contour if the vascular margin was rough or had a 'sawtooth' appearance.
Stent size (length and diameter) was defined as the actual implanted stent size. Excess stent length was defined as the remaining length of lesion length subtracted from stent length for each target lesion.
Stent-placement techniques
After induction of general anaesthesia or local anaesthesia, a 6-French guiding catheter ('Envoy', Cordis, USA; 'Guider softtip XP', Boston Scientific, Natick, MA, USA) was advanced to the distal cervical internal carotid artery or vertebral artery through a 6-French femoral arterial sheath. Under roadmap guidance, a 0.014-inch microwire ('Luge', 'Choice PT', 'PT Graphix', or 'PT2', Boston Scientific, Natick, MA, USA) was carefully steered through the target lesion and was fixed distally to support the delivery of the stent system. If the diameter of the stenotic lesion was considered to be smaller than the profile of the stent catheter, pre-dilatation was performed with an undersized balloon ('Maverick', Boston Scientific, Natick, MA, USA). The following bare metal balloon-expandable stents with different diameters and lengths were used to treat the lesions of variable sizes in this study: 'Invastent VOLO', Invatec, Brescia, Italy; 'Jostent flexmaster', JOMED GmbH, Rangendingen, Germany; 'Amg', AMG Raesfeld-Erle, Germany; and 'Apollo', MicroPort Medical, Shanghai, China. Stents were sized to match the diameter of the smallest normal adjacent vessel and to cover the entire length of the atherosclerotic lesion. The stents were deployed with the slow inflation of the balloon to its nominal pressure over a period of 30 s. Technical success was defined as the complete coverage of the lesion with less than 50% residual stenosis.
Heparin was given to all of the patients intraprocedurally to achieve a target activated clotting time of 250e300 s. All patients were pretreated with 100 mg aspirin and 75 mg clopidogrel daily for at least 3 days before the intervention and were discharged on the same treatment. All treated patients were required to follow the dual anti-platelet regimens for at least 6 months after stent implantation. Provided that no ISR had developed, clopidogrel was withdrawn and aspirin continued indefinitely.
Clinical and angiographic follow-up
Clinical follow-up information was obtained on each patient through review of medical records, personal interview or telephone contact at 1, 3, 6 and 12 months, and yearly thereafter. All neurologic events were recorded as clinical end points, including any death, TIA or stroke with 30 days after the initial procedure.
All patients were informed of an angiographic follow-up at 6 months after the initial procedure, or earlier in the case of either recurrent TIA or acute ischaemic stroke. ISR was recorded as an angiographic end point. The patients with symptomatic ISR were encouraged to undergo attempted repeat angioplasty with/without stent placement.
Angiographic assessment
Quantitative angiographic analysis was performed before and immediately after the procedure, and at the follow-up by two experienced operators blinded to the study purpose using the GE Advanced Workstation (AW 4.2_0.4). Matched views were selected for angiograms recorded. Lesion length, reference diameter (RD) and minimum lumen diameter (MLD) were measured before and immediately after stenting and at follow-up using the contrast-filled guiding catheter as the reference standard. The other variables obtained were lesion contour (irregular or smooth), lesion eccentricity or concentricity and lesion ulceration. The degrees of the initial and residual stenosis were calculated using the WASID technique. 3 
Data collection and analysis
Clinical and angiographic data at the time of the initial procedure and during follow-up thereafter were collected from the NSRP. 12 On the basis of earlier experience with primary angioplasty and stent treatment, some potential variables for restenosis were chosen and listed in Tables 2e4. Univariate and multivariate analyses to assess associations of these variables with ISR were performed.
Continuous data are presented as mean AE standard deviation; categorical data are presented as the count (percentage). Continuous variables were compared using unpaired Student's t-test and categorical data with Fisher's exact test. Cross tables (2 Â 2) were constructed to calculate the risk ratio (RR) with 95% confidence intervals (CIs) for the development of ISR with clinical, angiographic and procedural variables. To control for the errors that resulted from possible deviations of the continuous variables from a normal distribution, this analysis was verified by the ManneWhitney U test, which produced similar results. A multivariate Cox regression model with stepwise removal of non-significant variables was used to identify predictors for ISR. The variables listed in Tables 2e4 were entered in the stepwise multivariate Cox regression analysis. The entry and removal probability of stepwise selection were 0.1 and 0.2, respectively. A P value <0.05 was considered statistically significant. We performed a KaplaneMeier survival analysis on ISR and neurologic events during follow-up (including any death, TIA or stroke within 30 days of the initial procedure). All statistical analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, USA).
Results
During a 5-year period, a total of 84 patients with 90 intracranial atherosclerotic lesions underwent attempted treatment with single bare metal balloon-mounted stents. The mean age of the patients was 58.8 AE 11.7 years (range, 36e80 years), and 78.6% were male. The qualifying events before stenting were ischaemic strokes in 71.1% and TIAs in 28.9%. The median interval between the qualifying event and procedure was 25 days (range, 7e280 days). Patient characteristics are presented in Table 1 . The overall success rate of stent delivery was 87 of 90 lesions (96.7%). The lesion locations with failure to delivery were in one intracranial internal carotid artery and one middle cerebral artery because the stents could not cross the tortuous vessels. In addition, unsuccessful reduction of the stenosis to <50% occurred in one patient because of a heavily calcified intracranial carotid lesion. The mean stenosis before treatment was 74.81 AE 10.02%, with a reduction of stenosis to 18.84 AE 8.25% immediately after the stenting.
The rate of stroke and/or death within 30 days was 4.76% (4/84). The one death was due to a major stroke 2 weeks after stenting. All nonfatal complications included two ischaemic strokes (caused by perforator occlusion) and one intracranial haemorrhage (hyperperfusion related). There were no TIAs within 30 days.
Clinical and angiographic outcome during follow-up
All patients who survived the first month were followed up clinically. Median follow-up time was 9 months (range, 3e58 months). Recurrent neurologic events occurred in six patients: four had a TIA and two had a stroke. Only one patient died due to pneumonia. KaplaneMeier survival analysis revealed that neurologic event-free survival was 82.9% at 24 months after stenting (Fig. 1) .
Catheter-based angiographic follow-up was available for 61 patients with 65 lesions at a median of 7 months (range, 5e30 months). More than 90% of angiographic follow-up evaluations were performed between 6 and 10 months. Only one lesion was imaged at less than 6 months after stent placement. Twenty-three patients with 25 stents did not have angiographic follow-up. Baseline characteristics for the subsets of patients with or without angiographic follow-up were similar (Table 1) . Eighteen patients (18/61, 29.5%) with 20 lesions (20/65, 30.8%) were found to have ISR. However, using the KaplaneMeier method, the cumulative 12-month ISR rate was 50.6%. By 10 months, all ISR had occurred in this study (Fig. 2) . Of 18 patients with ISR, three were symptomatic, but others were asymptomatic. One patient presented recurrent ischaemic stroke due to completely in-stent thrombosis subsequent to ISR at 7 months after stenting. The other two patients experienced TIAs. The three patients refused to be retreated with angioplasty or stent placement. 
Factors influencing in-stent restenosis
Univariate analysis In our study, diabetes mellitus was the unique clinical parameter associated with ISR (diabetes vs. non-diabetes: RR, 4.143; 95% CI, 1.287e13.339, P Z 0.014), whereas age, sex, hypertension, hyperlipidaemia, smoking, history of coronary artery disease and time from QE to stenting were not ( Table 2 ). The incidences of ISR in Mori A, Mori B and Mori C lesions were 12%, 40.6% (Mori B vs. Mori A: RR, 5.018; 95% CI, 1.241e20.295; P Z 0.020) and 50% (Mori C vs. Mori A: RR, 7.333; 95% CI, 1.168e46.052; P Z 0.042), respectively (Table 3) ; lesions with ISR had longer length than those without ISR (P Z 0.009); the angiograms of typical cases are shown in Fig. 3 . Otherwise, lesions with irregular contour were slightly more prone to ISR than those with smooth contour, but this trend did not reach statistical significance (P Z 0.066). Other angiographic lesion parameters did not contribute to ISR (Table 3) .
Considering the procedural variables, stent diameter was statistically a significant risk factor of ISR with univariate analysis. Increased ISR rate was associated with stents that had small diameter (P Z 0.029). None of the other procedural variables studied were associated with increased ISR including the type of stent, stent length and excess stent length (Table 4) .
Multivariate analysis
Using stepwise multivariate Cox regression analysis, diabetes mellitus (HR, 2.661; 95% CI, 1.044e6.787; P Z 0.040) and lesion length (HR, 1.206; 95% CI, 1.023e1.421; P Z 0.026) were independently associated with increased risk of ISR (Table 5) .
Discussion
The present study showed that ISR after single bare metal balloon-mounted stent placement affected about one-third of the intracranial lesions performed by this intervention. Besides, we demonstrated that diabetes and lesion length were the two independent predictors for ISR.
In this angiographic follow-up case series, ISR occurred in 30.8% lesions, slightly lower than those reported by Siddiq et al 15 and the Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA) study 5 (33.8% and 32.4%, respectively), but higher than most of the published case series treated with balloonexpandable stents 7,9,16,17 (7.5e20.25%). The ISR incidence as estimated by the KaplaneMeier curve was 50.6% at 12 months after stenting in the present study. The differences in patient selection, stroke risk factors, lesion distribution, morphological characteristics of the lesion, stent type, method of analysis and follow-up duration may explain the variable ISR rates to some degree.
Cox regression analysis in the present study showed that diabetes was a strong predictor for ISR after intracranial stenting, and it was consistent with the previous published data. 5, 9 Accumulating evidences showed that patients with diabetes have a higher occurrence of ISR in coronary stenting. 18, 19 Undoubtedly, the pathogenesis of ISR is mainly characterised by neointimal hyperplasia 20 and diabetes mellitus can enhance neointima after coronary intervention. 21 The exact mechanisms responsible for this phenomenon remain to be uncovered, but one potential mechanism is that diabetes promotes inflammatory cell recruitment and abnormal extracellular matrix production. 22 However, it is unclear whether the ISR rate can be reduced by improved metabolic control in diabetes. Further studies are required to elucidate the effect of strict glycaemic control on ISR rates in diabetic patients.
The other strong independent predictor for ISR identified in our study was lesion length. In the recent long-term follow-up study of middle cerebral artery stenting, Miao et al. 9 also found a trend towards a greater rate of ISR in long-lesion, although this trend did not reach statistical significance. In addition, lesion length has also been suggested having great predictive value for ISR in the coronary intervention and vertebral artery origin stenting. 23, 24 A longer lesion means greater plaque burden and increased probability of smooth muscle cell proliferation and migration to neointima, 25 which may be one of the underlying mechanisms leading to the intracranial ISR. Mori classification was initially developed to predict the risk of clinical complications and restenosis after intracranial primary angioplasty. 11 Mori A lesions tend to have better clinical and angiographic outcomes than Mori B and Mori C lesions, which are longer, more eccentric, severer angulated and more occlusive. In the present study, it was also found that the Mori B or Mori C lesions had higher rate of ISR than Mori A lesions by univariate analysis. However, the similar results were not observed by multivariate analysis, possibly because the number of Mori C lesions was small.
In the present study, stent diameter was, on average, slightly (0.26 mm) smaller in patients with ISR. The stent was chosen on the basis of the diameter of the smallest normal parent vessel, thus providing a surrogate indicator of vessel size. Previous studies suggested that ISR after intracranial stenting was associated with smaller vessels treated in their case series. 5, 7 Our study also showed that the smaller vessels were more susceptible to ISR using univariate analysis; however, this factor was not detected as a significant independent predictor for ISR (P Z 0.074) by multivariate analysis. In addition, a recent report failed to show a relation between stent length or stent type and intracranial ISR. 9 Previous studies identified that various stent designs, multiple stents, stent length, excess stent length and overlapping stents were independent predictors for ISR after coronary intervention. 23, 26, 27 The present analysis of lesions receiving single stent of variable length eliminates the potential confounding influence of multiple stents and stent overlap on ISR, but stent length and excess stent length were not still found to be risk factors for ISR.
Several limitations of the current study should be considered. First, the stents used are not standardised in that only a minority of intracranial lesions were treated with dedicated intracranial stents and the majority were placed by non-dedicated intracranial stents designed for coronary arteries. This may influence potentially rate of restenosis and clinical complications. Second, the total number of patients is relatively small and angiographic follow-up of all patients is incomplete, which may thus limit statistical power and bias our results in this retrospective and single-centre study. Clearly, prospective and multi-centre studies including larger sample size are needed to confirm the results of the present study.
In conclusion, symptomatic intracranial atherosclerotic stenosis can be treated safely and effectively with bare metal balloon-mounted stents. However, ISR after intracranial stenting with bare metal balloon-mounted stents in our study seems to be more frequent than those reported by the majority of previous series studies, and is associated with diabetes and lesion length.
